Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05913037 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 6, 2025 (before its estimated August 19, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 162 to confirmed 167
    • Primary completion date: Jun 30, 2025 to Aug 19, 2025
    • Site details revised at 15 of 15 sites
    v4
  2. Study sites: 1 to 15v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 16, 2023 to Jun 20, 2023
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A study to evaluate the efficacy of FCN-159 in adult patients with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas.
Trial Details
NCT Number NCT05913037
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions
(from sponsor)		 Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Related terms Neurofibroma, Plexiform, Neurofibromatosis 1
Enrollment 167 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov